Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
about
Hemostatic management of patients undergoing ear-nose-throat surgeryStructures of Cytochrome P450 2B4 Complexed with the Antiplatelet Drugs Ticlopidine and Clopidogrel,The Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityFluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4Use of genetic data to guide therapy in arterial disease.Tales from the war on error: the art and science of curating QSAR data.Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapyAntiplatelet drug interactions with proton pump inhibitorsEffectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison.Personalized approaches to clopidogrel therapy: are we there yet?An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.Detection and characterization of ticlopidine conjugates in rat bile using high-resolution mass spectrometry: applications of various data acquisition and processing tools.Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.Antiplatelet resistance and thromboembolic complications in neurointerventional procedures.Effect of grapefruit juice on the bioactivation of prasugrelEfficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI).The role of human carboxylesterases in drug metabolism: have we overlooked their importance?Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication.Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers.The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel responseA phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivityA screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrelSpecies Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel.Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patientsA comparison of the metabolism of clopidogrel and prasugrel.Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.Thienopyridines in Acute Coronary Syndrome.The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.Prasugrel resistance: fact or fiction.Clopidogrel pharmacogenetics: metabolism and drug interactions.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
P2860
Q26771864-9F816473-5C13-4F33-8FF6-1E78CE04F14CQ27664259-DA985FB6-59D0-4F2F-BE46-9019D962E221Q28080256-E5AE1DE5-94D7-4BB1-8B9F-4C7DFDFB3F9BQ28307990-C4949FCC-6F00-4373-BCF5-7DF96ECBD1AEQ30978916-56706463-FAAC-4C2B-8ED1-427C65B57D4EQ30988299-EACE5997-255B-459B-A5BF-0D5F2076390FQ33561577-33B9FB4C-CB19-4CCB-A6E0-B43DD1F1620DQ33770184-8E5E3FB1-3196-40D2-BAB7-A6FD15409496Q33791290-FE9DA055-6B47-45DB-B4A1-381DD1057518Q33948811-B7395609-3957-4D77-94F8-9F0FED9081A4Q33963651-ABB38EA3-090E-4AF3-96AD-AFDB632D2477Q34371979-FE9A3017-281E-4175-ACC6-FBEB3351AB26Q34460548-E4591BE6-229F-45C4-94FE-D8E7B11B1E1DQ34577974-756F9CE9-FDAA-4E6A-80A9-C36F003C0662Q34621020-1E981A27-1453-4645-99BC-8F1FC755F0C0Q34702595-F692FAAC-698A-4300-913A-BED507B891C1Q35204942-F25837F7-C347-4644-A2D8-3F028C0D8C30Q35640465-992AA028-F435-4C0E-86B5-4A85D28632CEQ35750126-A344AB0A-774A-401F-B336-D8A3560FADF6Q35846138-0BB14AAE-F2F5-4B87-934B-A1A903F0362DQ36046658-70743EE2-099D-4AC9-80AD-D5F9040E657BQ36066647-17072223-0884-4A17-B152-973DC32EF105Q36709028-8CDF56C8-8861-4BB0-A9F8-194B9B014360Q36723867-CA61DF59-D76C-40DC-A276-5053CD689795Q36928556-1602BA6A-F0A3-47A8-B617-8153DE7A3C24Q36948107-31E9725C-90F7-4023-BA19-89B51337809FQ37316562-9ED587BE-77D6-4089-98A1-ED2BEAE1DB14Q37319541-49919B49-9983-4E92-BC78-F296FF8AB1A5Q37506535-1CE2273A-4011-4BEF-AE2C-A999C41097F9Q37605071-125A67FA-3AE1-4082-A68E-6728C592BB0FQ37788682-1E060559-7A3A-4AE8-A862-2C0D6367ED02Q37818331-14A9F235-5B54-40D2-9D4F-393546A83CE9Q37831317-17ECD109-78FF-4B87-B328-9F2385E90AB2Q37835616-03FB56E9-8DBF-40EB-A5DC-E1FA1751026EQ37838124-42AB486C-07AE-40A0-A667-6E5EB3B87AA3Q37853071-82D2FCB0-B9EC-4E33-8648-BABB7CB036D1Q37882712-E7ED43B0-FC11-40A4-A6F0-43B543C1169AQ37905028-2103D940-CC66-4BB7-90B6-2A8E6336894DQ37912178-E99500D3-2138-42E3-91D8-09C64A6980D5Q37923969-0AAB0BC4-6EDC-4728-9EF4-120BA6FCDABB
P2860
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Metabolism and disposition of ...... grel, and prasugrel in humans.
@en
Metabolism and disposition of ...... grel, and prasugrel in humans.
@nl
type
label
Metabolism and disposition of ...... grel, and prasugrel in humans.
@en
Metabolism and disposition of ...... grel, and prasugrel in humans.
@nl
prefLabel
Metabolism and disposition of ...... grel, and prasugrel in humans.
@en
Metabolism and disposition of ...... grel, and prasugrel in humans.
@nl
P2093
P2860
P356
P1476
Metabolism and disposition of ...... grel, and prasugrel in humans.
@en
P2093
Atsushi Kurihara
Nagy A Farid
Steven A Wrighton
P2860
P304
P356
10.1177/0091270009343005
P577
2009-11-30T00:00:00Z